Table 1.

Clinical trials of STAT3 oligonucleotide inhibitors

Oligonucleotide	Formulation	Company or sponsor	Indication	Stage of development	Status
STAT3 DECOY	DNA competitive inhibitor	University of Pittsburgh	Head and neck cancer	Phase 0	Completed
AZD9150	Antisense Oligonucleotide inhibitor	AstraZeneca, Ionis Pharmaceuticals	Diffuse large B-cell lymphoma, advanced lymphoma	Phase I/II	Active, not recruiting
AZD9150	Antisense Oligonucleotide inhibitor	National Cancer Institute (NCI)	Ovarian cancer/neoplasms, gastrointestinal cancer/neoplasms	Phase II	Terminated
AZD9150	Antisense Oligonucleotide inhibitor	AstraZeneca, Ionis Pharmaceuticals	Advanced adult hepatocellular carcinoma, metastatic hepatocellular carcinoma	Phase I	Completed
AZD9150 in combination with MEDI4736	Antisense Oligonucleotide inhibitor Monoclonal anti-PD-L1 monoclonal antibody	MedImmune	Diffuse large B-cell lymphoma	Phase I	Recruiting
AZD9150 in combination with MEDI4736	Antisense Oligonucleotide inhibitor Monoclonal anti-PD-L1 monoclonal antibody	AstraZeneca, MedImmune	Metastatic head and neck squamous cell carcinoma	Phase I/II	Recruiting
AZD9150 in combination with MEDI4736	Antisense Oligonucleotide inhibitor Monoclonal anti-PD-L1 monoclonal antibody	M. D. Anderson Cancer Center, AstraZeneca	Advanced pancreatic, non-small cell lung and colorectal cancers	Phase II	Not yet recruiting

Information collected from http://www.clinicaltrials.gov